Airway microbiota in severe asthma and relationship to asthma severity and phenotypes by Zhang, Q et al.
RESEARCH ARTICLE
Airway Microbiota in Severe Asthma and
Relationship to Asthma Severity and
Phenotypes
Qingling Zhang1,2,3☯, Michael Cox1☯, Zhike Liang1,2,3, Folke Brinkmann1, Paul
A Cardenas1, Rachael Duff1, Pankaj Bhavsar1,2, William Cookson1,2‡, Miriam Moffatt1,2‡,
Kian Fan Chung1,2,3‡*
1 National Heart & Lung Institute, Imperial College, London, United Kingdom, 2 Respiratory Biomedical
Research Unit, Royal Brompton & Harefield NHS Trust and Imperial College London, United Kingdom,
3 State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital, Guangzhou Medical University,
Guangzhou, China
☯ These authors contributed equally to this work.
‡ These authors are joint senior authors on this work.
* f.chung@imperial.ac.uk
Abstract
Background
The lower airways harbor a community of bacterial species which is altered in asthma.
Objectives
We examined whether the lower airway microbiota were related to measures of asthma
severity.
Methods
We prospectively recruited 26 severe asthma, 18 non-severe asthma and 12 healthy sub-
jects. DNA was extracted from induced sputum and PCR amplification of the V3-V5 region
of bacterial 16S rRNA gene was performed.
Results
We obtained 138,218 high quality sequences which were rarefied at 133 sequences/sam-
ple. Twenty OTUs had sequences1% of total. There were marked differences in the distri-
bution of Phyla between groups (P = 2.8x10-118). Bacteroidetes and Fusobacteria were
reduced in non-severe and severe asthmatic groups. Proteobacteria were more common in
non-severe asthmatics compared to controls (OR = 2.26; 95% CI = 1.94–2.64) and Firmi-
cutes were increased in severe asthmatics compared to controls (OR = 2.15; 95%CI =
1.89–2.45). Streptococcal OTUs amongst the Firmicutes were associated with recent onset
asthma, rhinosinusitis and sputum eosinophilia.
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Conclusions
Sputum microbiota in severe asthma differs from healthy controls and non-severe asth-
matics, and is characterized by the presence of Streptococcus spp with eosinophilia.
Whether these organisms are causative for the pathophysiology of asthma remains to be
determined.
Introduction
Asthma is a common airway condition characterized by airway inflammation and intermittent
episodes of airflow obstruction. That asthma is a syndrome consisting of different phenotypes
has been recognised for a long time by clinicians [1]. Features such as the onset of asthma
either in childhood or during later years, the presence of atopy, the effect of upper respiratory
tract viral infections in inducing exacerbations of asthma, asthma induced by ingestion of aspi-
rin or non-steroidal anti-inflammatory agents, and the concomitant presence of comorbidities
such as rhinosinusitis or obesity, have been recognised as important clinical features that delin-
eate certain asthma clusters [1, 2]. In addition, asthma may be categorised by the severity of
chronic symptoms and by the occurrence of recurrent exacerbations of asthma despite treat-
ment with maximal asthma medications including corticosteroids [3]. T-helper type 2 cells
[Th2] are recognised as an important underlying mechanism of a specific asthma phenotype
that is associated with high levels of circulating IgE and atopy, and eosinophilia [4, 5] The pres-
ence of eosinophils in sputum samples has been known to be associated with asthma and has
been used to indicate a good therapeutic response to inhaled or oral corticosteroid therapy [6,
7]. On the other hand, those with neutrophilic inflammation have been linked to corticosteroid
insensitivity and in some instances to bacterial infections and colonisation [8, 9].
Consistent epidemiological indications of the importance of the microbiome in asthma
include the protection afforded by a rich microbial environment in early life [10, 11], observa-
tions that the bronchial tree contains a characteristic flora that is disturbed by the presence of
pathogens in asthma [12–14], birth cohort studies showing that the presence of the same path-
ogens in throat swabs predicts the later development of asthma [15], recognition that these bac-
teria have consistently been associated with exacerbations of asthma [16], and evidence for the
efficacy of antibiotics in the treatment of asthma and related syndromes [17–19]. In 27% of
asthmatic patients presenting with an exacerbation of asthma, bacteria have been cultured
from sputum samples, with Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus
aureus,Moraxella catarrhalis and Haemophilus influenzae being the most frequent bacteria
isolated [20]. This spectrum of bacterial species was also isolated from induced sputum samples
in 15% of patients during a stable period of asthma [8]. In addition, other species such asMyco-
plasma pneumoniae and Chlamydophila pneumoniae have also been detected in patients with
asthma [21]. Using a terminal restriction fragment length polymorphism profiling for bacterial
community analysis, another study showed that the dominant species within the airway bacte-
rial community in sputum samples from treatment-resistant asthma wasMoraxella catarrhalis
or a member of the Haemophilus or Streptococcus genera [22].
16S ribosomal RNA microarray rather than conventional culture techniques have been used
recently to detect operational taxonomic units in lower airway epithelial samples. This tech-
nique has led to the detection of a microbiome in the lower airways of normal subjects that has
hitherto been considered to be a sterile environment. In addition, airways of asthmatic subjects
were reported to show a different microbiota compared to non-asthmatic subjects in terms of
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an increase in Proteobacteria particularly inHaemophilus,Moraxella, and Neisseria spp, with a
reduction in Bacteroidetes [12]. Another study confirmed the increase in bacterial load particu-
larly Proteobacteria in the lower airways of asthmatics, and the total bacterial burden and
diversity correlated with bronchial hyperresponsiveness [13]. In induced sputum, a higher pro-
portion of Proteobacteria with lesser content of Firmicutes and Actinobacteria in asthmatics
compared to non-asthmatics was reported. By contrast, no differences in airway bacterial load
were observed between subjects with asthma and normal control subjects as assessed by 16S
rRNA copy number [23]. Neonates colonized in the hypopharyngeal region with S. pneumo-
niae,H. influenzae orM. catarrhalis, or with a combination of these organisms were at
increased risk for recurrent wheeze and asthma early in life [15]. In neonates from the tropics,
the increased prevalence ofHaemophilus and Staphylococcus spp was proposed to contribute to
wheezing illnesses [14]. Whether they contribute to asthma pathogenesis or whether they are
altered as a consequence of asthma is at present unresolved [24]. However, the role of patho-
gens in causing disease and the actions of commensal bacteria in maintaining a healthy mucosa
in the gut are well-recognised [25].
Previous studies of the airway microbiome showed that that the airways of moderate asth-
matics contained an excess of Proteobacteria [12, 26] compared to normal controls, but asthma
is heterogeneous in its clinical presentation and severity [3, 27] and it is possible that the air-
ways of severe asthmatics have a different microbiota. In stable asthma patients with more
severe disease, up to half had one or more bacteria cultured from sputum, withH. influenzae,
P. aeruginosa and S. aureus being the most common [28]. It is therefore extremely valid and
important to examine the respiratory microbiota in patients with severe asthma and determine
whether the airway microbiota is altered compared to mild-moderate asthma as these differ-
ences could be important in determining both the pathophysiology and treatment of severe
asthma. Therefore, we have determined whether patients with severe asthma have an altered
microbiota compared to non-severe asthma measured by high throughput sequencing of 16S
ribosomal RNA gene. More importantly, we also determined whether the altered microbiota
were associated with any particular phenotype of asthma.
Methods
This study was approved by the Ethics Committee of the Royal Brompton & Harefield NHS
Trust. All patients provided written informed consent to participate in this study by signing
the consent form that was approved by the Ethics Committee of the Royal Brompton & Hare-
field NHS Trust.
Subjects
All non-asthmatic subjects were healthy volunteers without any disease with normal spiromet-
ric results (Table 1). Patients with severe asthma were recruited from the Severe Asthma clinic
at the Royal Brompton Hospital, London, over a 6-month period. Patients with severe asthma
needed either continuous or near-continuous oral corticosteroids, high-dose inhaled cortico-
steroids, or both to achieve a level of mild-to-moderate persistent asthma, and by 2 or more
minor criteria [29]. All patients had been attending the clinic for at least 6 months and had
undergone a Severe Asthma Protocol for confirmation of the diagnosis of severe asthma [30].
Patients with non-severe asthma had controlled asthma as defined by no daytime or nocturnal
symptoms, no limitation of activities, minimal use of rescue medication while using up to
2,000 μg/d or equivalent of inhaled beclomethasone. Current smokers and ex-smokers of
greater than 5 pack years were excluded. Patients with an exacerbation of asthma within the
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last 4 weeks or with a respiratory tract infection requiring antibiotic treatment within 6 weeks
were excluded.
Lung function and atopic status
FEV1 and forced vital capacity (FVC) were measured using a spirometer (Erich Jaeger UK Ltd,
Market Harborough, UK). Atopy was defined by the presence of positive skin-prick tests to at
least one common aeroallergen including house dust mite, grass and tree pollen, cat dander,
dog dander and Aspergillus.
Sputum induction, cell count and microbiology
Sputum was induced by inhalation of an aerosol of sterile 3% saline solution and subsequently
increasing to 4% and 5% during 3 periods of 2 minutes each after the subject has had pre-treat-
ment with inhaled salbutamol [31]. Particular care was taken to avoid contamination with
saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their
nose after each inhalation. Sputum samples were collected into sterile pots. Peak flow
Table 1. Characteristics of the subjects1.
Parameters Healthy Non-severe asthma Severe asthma
Number 12 18 26
Age (years) 35.4±10.3 45.2±16.0 47.9±10.9**
Gender (male:female) 1:11 10:8 9:17
BMI (kg/m2) 24.5±5.7 26.9±4.7 28.9±6.2*
Duration of asthma (years) 0 29.7±19.3 22.6±16.5
Ex-Smoker (n) 0 3 0
Rhinosinusitis (n) 0 4 8
Atopy 4 (n) 0 9 24
IgE IU/L2 48.4 (26–80) 112.2 (14–510)** 148.4 (2–4335)** ¶
Daily prednisolone (mg.day-1) 0 0 17.5±9.3
Inhaled corticosteroids3 (μg.day-1) 0 1453±563 2348±1140¶¶
FEV1 (L) 3.78±0.63 2.88±0.94 2.25±0.60
FEV1 (% predicted) 98.7±11.0 87.0±15.3 76.7±15.9
FVC (L) 4.69±0.59 3.89±0.98 3.25±0.74
FVC (% predicted) 101.8±6.3 99.8±14.7 92.0±11.7
Bronchodilator reversibility5 (%) Not done 14.4±10.0 17.9±12.1
Blood eosinophils (per μl) 0.10±0.0 0.28±0.17** 0.40±0.51
Sputum eosinophils (%) 0.4±0.4 6.9±12.4 19.4±26.9** ¶
Sputum neutrophils (%) 49.6±27.6 45.7±24.8 45.0±27.4
1 Data shown as mean ± SD unless otherwise denoted.
2 Data shown as geometric mean and range.
3 Inhaled corticosteroid expressed as beclomethasone propionate equivalent dose
4 Atopy deﬁned as by the presence of positive skin-prick tests to at least one common aeroallergen.
5 Bronchodilator reversibility calculated as postbronchodilator FEV1-prebronchodilator FEV1/prebronchodilator FEV1 x 100.
BMI: Body mass index; FEV1: forced expiratory volume in one second; FVC: forced vital capacity.
*P<0.05 compared to healthy controls;
**P<0.01 compared to healthy controls;
¶P<0.05 compared to non-severe asthma;
¶¶P<0.01 compared to non-severe asthma.
doi:10.1371/journal.pone.0152724.t001
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measurements were made after each inhalation. The procedure was not carried out if the sub-
ject brought up spontaneously sputum and if the baseline post-bronchodilator FEV1 was less
than 60% predicted or less than 1.0 litre. If there was a fall in peak flow of 20% or more or if
symptoms occurred during the procedure, the induction was stopped.
For sputum bacteriological culture, an aliquot of induced sputum was selected using a posi-
tive displacement pipette and used for quantitative bacteriological culture [30]. Sputum plugs
were selected and one portion was used to perform differential cell counts. To perform differ-
ential cell counts, di-thiothreitol was added to the sputum plug and mixed vigorously on a
plate shaker to solubilize the sputum. Cytospins were then prepared, and differential cell counts
obtained.
For sputum 16S RNA assay, sputum plugs weighing more than 0.1g were selected and
placed in a 1.5 ml sterile polypropylene centrifuge tube for DNA extraction.
DNA extraction and PCR amplification and sequencing
DNA extraction was performed using the QIAmp DNAMini Kit extraction kit, modified to
include a bead-beating step. The method proceeded as per manufacturer’s instruction until the
end of the Proteinase K incubation, when the sample and lysis buffer were transferred to lysing
matrix E bead-beating tubes (LME tubes; MP Biomedicals), and beaten in a Precellys bead-
beater (Bertin Technologies) for 2 cycles of 30 seconds at 6800 rpm. DNA was eluted from the
QIAmp columns in 40 μl of nuclease free water and stored at -80°C until further use.
PCR amplification of the V3-V5 region of the 16S rRNA gene was performed using 1 μl of
extracted DNA template. Reactions were performed in quadruplicate using primer pair 357F/
926R (357F - CCTACGGGAGGCAGCAG, 926R - CCGTCAATTCMTTTRAGT), coupled with
Roche 454 sequencing adaptors A (reverse primer) and B (forward primer) and a unique 12
base-pair barcode [32]. Replicates were combined and purified twice using Ampure XP (Beck-
man Coulter) bead purification, before quantification using the Quant iT kit (Life Technolo-
gies) and equimolar pooling. Thirty to fifty samples were pooled in each sequencing run on a
Roche 454 Junior pyrosequencer, using the Lib-L kit and protocol (Roche Diagnostics Ltd).
Data pre-processing
Raw sequence files from each run were combined prior to denoising and chimera removal in
QIIME [33] using Ampliconnoise and Perseus [34]. Operational taxonomic units (OTUs) at
97% identity were picked using UCLUST [35], the most abundant sequences in each OTU
selected as representatives and classified using the RDP classifier [36] retrained with the Silva
database version 111 [37]. Random resampling of the OTU table to 133 reads was performed
in order to ensure equal sequence depth of each sample, whilst maintaining the ability to dis-
criminate between samples, resulting in 3458 analysed.
Data analysis
Statistical analyses of phenotypic relationships were all carried out using IBM SPSS version 21.
Asthma status was coded as non-asthmatic = 0, non-severe asthma = 1, and severe asthma = 2.
The complex relationships between phenotypic variables were explored with Principal Compo-
nents Analysis (PCA) in the FACTOR routine in SPSS. Missing values were replaced with the
study mean for the relevant parameter. PCs with an eigenvalue>1 were retained in the analy-
sis, and a varimax rotation was applied. Bacterial counts were log-normalised after adding 1 to
each count (to return a log value of 0 when the count was 0) before parametric analyses. Analy-
ses of community diversity were carried out in the R statistical environment using the Phyloseq
and Vegan packages.
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Results
Patient characteristics
The study population consisted of 56 subjects (12 normal subjects, 18 non-severe asthmatics
and 26 severe asthmatics) (Table 1). Severe asthmatics had lower %FEV1 predicted (P<0.05)
and higher sputum eosinophil counts (P<0.05), and higher BMI and atopy compared to non-
severe asthma and normal subjects. 15 of the 26 severe asthma patients were on daily oral pred-
nisolone using a mean dose of 17.5 mg per day.
Out of the 56 samples, potentially pathogenic bacteria were cultured from the sputum of 5
stable severe asthmatics (3 x Haemophilus influenzae, 1 xMoraxella catarrhalis and 1 x Staphy-
lococcus aureus) and 5 stable non-severe asthmatics (1x, 2x and 2x respectively). No potentially
pathogenic bacteria were cultured from the 12 healthy controls.
PCA analysis of clinical variables
PCA was carried out with the most important phenotypic variables (Table 2). In order to avoid
over-fitting of the model, single variables were chosen to represent highly correlated related
parameters. Four Principal Components (PC1-4) with eigenvalues>1 and accounting for
>10% of the variance were identified (Table 2). Asthma status (from normal to severe asthma)
was most strongly associated with the first two PCs, PC1 and PC2 (Table 2).
PC1 was typified by asthma of relatively long duration, atopy, a relatively high BMI, the use
of inhaled steroids and long-acting β-agonist and a weak negative association with % sputum
eosinophils. PC2 was associated with poor lung function, oral corticosteroid use and sputum
eosinophilia. PC3 was typified by relatively recent onset, nasal disease, blood and sputum
eosinophilia, and relatively fewer neutrophils in sputum. PC4 was characterised by the rela-
tively increased age of the patients, poorer lung function and treatment with inhaled corticoste-
roids and long-acting β-agonist.
Table 2. Principal Components Analysis of phenotypic variables.
Component (% of total variance)
1 (24%) 2 (16%) 3 (15%) 4 (12%)
Diagnosis 0.663 0.525 0.191 0.273
FEV1 (% predicted) -0.117 -0.515 -0.227 -0.520
Asthma duration 0.526 -0.113 0.567
Atopic status 0.773 0.351 0.213
Rhinosinusitis 0.138 0.619 0.271
Body mass index 0.525
Age 0.139 0.149 0.802
Inhaled corticosteroids 0.860 0.101 0.318
Salbutamol use 0.379 0.671 -0.174
Long-acting β-agonist 0.836 0.118 0.364
Oral corticosteroids 0.202 0.895
Sputum neutrophils -0.750 0.247
Sputum eosinophils -0.188 0.532 0.602 0.215
Blood eosinophils -0.105 0.773 0.127
Principal Components accounting for <10% variance and vector coefﬁcients < 0.1 are not shown.
doi:10.1371/journal.pone.0152724.t002
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Operational taxonomic units (OTUs)
We obtained a total of 138,218 high quality sequences after de-noising and chimera removal.
Following exclusion of singletons, 163 OTUs remained. Samples were rarefied at 133 sequences
per sample for statistical analyses, such that a total of 7448 reads were used for subsequent
analyses. Rarefaction with higher numbers of sequences reduced the numbers of subjects but
did not change the principal findings of the study. Many of the OTUs were relatively uncom-
mon, and we found 31 OTUs with numbers of sequences that were0.5% of the total, 20
OTUs with sequences1% of the total and 10 OTUs which made up2% of the total. Because
statistical power to detect associations to uncommon OTUs is limited, we confined down-
stream analyses to the 20 OTUs with sequences1% of the total. We further excluded an OTU
identified as Burkholderia (1.3% of total reads) because it was confined to three subjects and
our kit controls indicated it to be a common contaminant.
The most common phylum in the dataset was Firmicutes, containing 35.4% of sequences,
followed by Bacteroidetes with 27.5% and Proteobacteria with 24.5%. There were marked dif-
ferences in the distribution of Phyla between the three patient groups (χ2 = 530, 5 d.f.;
P = 2.2x10-112) (Fig 1).
Comparison between healthy controls and patients with non-severe asthma showed a
reduction in the prevalence of Bacteroidetes, containing OTUs identified predominately as
Gram-negative anaerobes such as Prevotella spp. (Odds Ratio (OR) = 0.62; 95% confidence
interval (CI) = 0.54–0.71) and Fusobacteria (OR = 0.50; 95%CI = 0.40–0.63) (Fig 1), whereas
Proteobacteria, containing potential respiratory pathogens such as, Neisseria andMoraxella
spp., were more common in the patients with non-severe asthma compared to controls
(OR = 2.26; 95%CI = 1.94–2.64).
Bacteroidetes and Fusobacteria were also reduced in the severe asthma group compared to
healthy controls (OR = 0.62; 95% CI = 0.54–0.70 and OR = 0.38; 95% CI = 0.31–0.48, respectively)
(Fig 1). A minor increase in Proteobacteria was also seen in the severe asthmatics (OR = 1.21;
95% CI = 1.03–1.40) compared to non-asthmatic controls, but this was much less striking than
the increase observed in Firmicutes, consisting predominately of streptococcal OTUs (OR = 2.15;
95% CI = 1.89–2.45). The increased presence of Firmicutes in severe asthma was also evident in
comparison with the non-severe asthma group (OR = 2.15; 95% CI = 1.92–2.41) (Fig 1).
These results are consistent with earlier studies that show a reduction in Bacteroidetes and
an increase in Proteobacteria in adults and children with asthma [12, 14]. Our present results
also indicate that the microbiota of severe asthmatics differs from that of non-severe asth-
matics, and is characterized by an increase in the prevalence of Firmicutes rather than
Proteobacteria.
We next looked for differences closer to the species level, defined by particular OTUs. These
two Streptococcus OTUs were positively correlated with asthma severity (Streptococcus_23,
r = 0.41, P = 0.002; and Streptococcus_15, r = 0.35, P = 0.009), and one Prevotella OTU showed
a negative correlation (Prevotella_292, r = 0.36, P = 0.007). Phylogenetic analysis of these
sequences was not able to further differentiate the Streptococcus OTUs into individual species.
Fig 2 shows the heat map of OTUs found in the sputum samples from asthmatic and non-asth-
matic subjects.
Repeating the PCA and including the individual counts for these three OTUs showed that
PC3 (relatively recent onset asthma with eosinophilia and nasal disease) was most strongly
related with the presence of the two Streptococcus OTUs (Table 3). Weaker relationships were
seen between Streptococcus_23 and PC1 (atopic disease treated with inhaled corticosteroid and
long-acting β-agonist), and Streptococcus_155 and PC2 (severe asthma with sputum eosino-
philia). PC2 was also associated with lower counts of Prevotella_292.
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Alpha diversity measures, species richness (the number of different OTUs), Pielou’s even-
ness (the skew or dominance of OTUs), Shannon and Inverse Simpson’s diversity indices, were
calculated for each sample. There were no significant differences in alpha diversity between
healthy, non-severe and severe asthmatics (Fig 3A). A Bray Curtis dissimilarity matrix was cal-
culated and PERMANOVA (Adonis) used to demonstrate that community structure was
Fig 1. Distribution of bacterial Phyla in healthy controls and non-severe and severe asthmatics defined by sequencing of the 16S rRNA gene. The
distribution of bacterial phyla from 12 healthy subjects, 18 non-severe asthmatics and 26 severe asthmatics are shown. Compared to healthy controls, non-
severe asthmatics showed a reduction in the prevalence of Bacteroidetes and Fusobacteria and an increase in Proteobacteria (all P<10−10). Severe
asthmatics showed an increase in Firmicutes compared to controls and non-severe asthmatics, together with reduction in Bacteroidetes and Fusobacteria
compared to controls (all P<10−10). The distribution of bacterial phyla is given in the accompanying lower Table as Operational Taxonomic Unit (OTU) counts
with % total in brackets. The legend gives the odds ratios for each comparison. The overall χ2 for differences in phyla between phenotypic groups = 557.7
(P = 2.8x10-118). *OUT counts (% total).
doi:10.1371/journal.pone.0152724.g001
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significantly different between disease groups and they explained 6% of the variance in com-
munity structure (P = 0.008, Fig 3B).
Discussion
This analysis of the microbiota in patients with non-severe and severe asthma is one of the
most substantial reported so far. We defined severe asthma as patients who remained uncon-
trolled despite taking sufficient amounts of asthma medication including corticosteroids, often
as systemic doses as well as via the inhaled route. Even in this modest number of subjects, we
found clusters of severe asthma such as those with poor lung function, oral corticosteroid use
and sputum eosinophilia. We found that there were marked differences in the distribution of
Phyla between groups. Our findings in patients with non-severe asthma are strongly consistent
with earlier studies showing an increase in Proteobacteria and a reduction in non-pathogenic
commensals when compared to controls [12, 14, 26]. We discovered equally distinctive
changes in the severe asthma group. Bacteroidetes and Fusobacteria, representing non-patho-
gens were reduced in both non-severe and severe asthmatic groups compared to the healthy
group, while Firmicutes were markedly increased in severe asthmatics. Amongst the Firmi-
cutes, we also found that 2 Streptococcus spp., Streptococcus_23 and Streptococcus_155, were
correlated with asthma severity. In addition, one OTU identified as Prevotella spp. showed neg-
ative correlation with asthma status. Though alpha diversity measures did not demonstrate a
difference between asthma subgroups, there were small significant differences in the whole
Fig 2. Heat map of operational taxonomic units (OTUs) found in the sputum of asthmatics and non-asthmatic subjects. The phylogenetic tree for the
principal (>1% of total) OTUs is shown at the left. On the right, increasing depth of colour indicates relative abundance of the OTU in an individual sample.
Major phyla are shown between the phylogenetic tree and the heat map. Proteo = Proteobacteria; Fuso = Fusobacteria.
doi:10.1371/journal.pone.0152724.g002
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community structure as determined using an analysis of beta diversity. Thus, the airway micro-
biota in severe asthma is different from the non-severe asthma patient, which is in turn differ-
ent from healthy controls. Furthermore, non-severe asthmatics demonstrated an increase in
Proteobacteria relative to either healthy controls or severe asthmatics.
In the study of Marri et al [38], who also used induced sputum samples from 10 non-asth-
matic and 10 adults with asthma not taking inhaled or oral corticosteroid therapy at the time of
the study, a greater abundance of Proteobacteria, particularly Haemophilus, and lower abun-
dance of Firmicutes was reported. The increase in Proteobacteria confirmed the results of ear-
lier studies [12, 13] using bronchial brushings from asthma patients who were on inhaled
corticosteroid treatment, where Haemophilus was particularly seen to be increased, with the
former study also reporting a decrease in Prevotella. Furthermore, our previous study [12], a
group of asthmatic children with difficult-to-treat asthma on high dose inhaled corticosteroids,
an increase in Proteobacteria/Haemophilus and Firmicutes/Staphylococcus or Streptococcus,
and a decrease on Bacteroidetes/Prevotella were observed in bronchoalveolar lavage fluid sam-
ples. Our current data focused on an analysis of sputum samples from patients with severe
asthma are consistent with the differences in phyla/genera previously reported between asthma
and controls. Recently, using bronchial brushings from the lower airways, Huang et al. have
reported that patients with severe asthma were significantly enriched in Actinobacteria com-
pared to healthy control subjects or patients with mild-to-moderate asthma, with the largest
differences seen in a member of the Klebsiella genus [39]. Whether the discrepancy between
our findings and that of Huang et al. is due to differences in the region of the lung is unclear at
present and would necessitate further investigation whereby intra-subject comparisons are
done of bronchial brushing versus induced sputum.
Asthma is a heterogeneous syndrome resulting from an interaction of different environ-
mental factors [such as allergens, smoking and medications] with host factors to produce
Table 3. Principal Components Analysis of phenotypic variables includingmicrobial associations.
Component (% of total variance)
1 (21%) 2 (15%) 3 (13%) 4 (12%)
Diagnosis 0.661 0.533 0.259 0.239
FEV1 (% predicted) -0.157 -0.471 -0.624
Asthma duration 0.668 -0.237 0.319
Atopic status 0.577 0.449 0.262
Rhinosinusitis 0.111 0.311 0.595
Body mass index 0.225 0.289 0.102
Age 0.388 0.661
Inhaled corticosteroids 0.934 0.173
Salbutamol use 0.362 0.693 -0.111
Long-acting β-agonist 0.923 0.175
Oral corticosteroids 0.897 0.207
Sputum neutrophils 0.176 -0.659 -0.243
Sputum eosinophils -0.134 0.326 0.471 0.525
Blood eosinophils 0.558 0.487
Streptococcus_155 0.106 0.334 0.707
Streptococcus_23 0.342 0.671
Prevotella_292 -0.120 -0.404 -0.111 -0.145
Principal Components accounting for <10% variance and vector coefﬁcients < 0.1 are not shown.
doi:10.1371/journal.pone.0152724.t003
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Fig 3. Diversity of microbial communities in healthy, non-severe and severe asthmatics. A. Boxplot of alpha diversity measures Species Richness and
Shannon’s Diversity Index, which are not significantly different between groups. B Non metric multidimensional scaling of Bray Curtis distance split by group
(stress 0.22). Here PERMANOVA (Adonis) indicates that community structure is significantly associated with asthma classification (P = 0.008) and this
variable explains 6% of the variance.
doi:10.1371/journal.pone.0152724.g003
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complex phenotypic manifestations [3, 27]. Phenotypic complexity can be simplified by statis-
tical procedures such as principal component analysis [PCA] which identifies the most impor-
tant variables and their correlations. PCA of the phenotypic data led to the definition of four
main principal components. The first 2 clusters had characteristics of severe asthma [3] and
were associated with the 3 bacterial species that were over- or under-represented in severe
asthma. Thus, in Cluster PC2, patients on oral corticosteroid therapy with an atopic back-
ground, sputum eosinophilia and airflow obstruction were more likely to be associated with
an increase of Streptococcus_155 and a decrease in Prevotella_292. On the other hand, Cluster
PC1 also representing a severe group not on oral corticosteroids but on high dose inhaled cor-
ticosteroids and long-acting β-agonist, with a long duration of asthma and non-atopic back-
ground, was associated with an increase in both Streptococcus _23 and Streptococcus_155, and
to some extent with a reduction in Prevotella_292. The greatest association with an increase in
Streptococcus_155 and Streptococcus_23 was seen in Cluster PC3, characterised by both blood
and sputum eosinophilia, but with a lower sputum neutrophil count, and nasal disease, with
an increased likelihood of being on oral corticosteroids. These associations in distinct clusters
of asthma may reflect the influence of specific elements of the microbiota on well-known
characteristics of severe asthma such as eosinophilia, chronic airflow obstruction and cortico-
steroid insensitivity [40]. Alternatively, asthma treatments [such as corticosteroid or β-adren-
ergic agonist therapies] or the differences between asthma subtypes may select for particular
microorganisms.
Several confounding factors particularly in the severe asthmatic subjects need to be taken
into consideration. First, the effect of asthma treatments on the airway microbiota remains
unclear. In addition to potential unknown effects on bacterial persistence and growth, these
medications may alter the innate immune response to bacteria that may in turn determine
their pathogenicity. By definition, the patients with severe asthma that we studied were already
on high doses of inhaled corticosteroids, often on oral corticosteroids. However, none were on
antibiotic therapy or had been in the past 6 weeks, as this was one of the major entry criteria.
The potential effect of corticosteroids on the lung microbiota is unclear, but comparing the
microbiota data of Marri et al. [38] where patients with asthma not on inhaled corticosteroids
were selected with those of Hilty et al. [12], there were no major differences that would indicate
an effect of inhaled corticosteroids. On the other hand, in the small study of the lung micro-
biome in patients with moderate to severe COPD, the alterations in lung microbiome reported
may have been accounted for by inhaled corticosteroid therapy [41]. The other important
observation is that the gut microbiota has been reported to completely metabolise corticoste-
roids such as prednisolone, beclomethasone dipropionate and budesonide, but the effect of the
airway microbiota in this context remains unknown [42]. The possibility that such an action by
selected bacteria to preferentially metabolise corticosteroids could underlie corticosteroid
insensitivity in severe asthma has not been tested.
The significance of the changes in sputum microbiota that we observed in severe asthma
suggests the need for further investigation. Since our patients with severe asthma may be classi-
fied as being corticosteroid-insensitive as demonstrated by studies on peripheral blood mono-
nuclear cells or alveolar macrophages [43, 44], the recent study by Goleva and colleagues on
bronchoalveolar lavage microbiota of patients defined as corticosteroid-resistant and cortico-
steroid insensitive is of interest [23]. In corticosteroid-resistant patients, they reported an
increase in the proportion of sequences of microorganisms in the phyla Actinobacteria and
Proteobacteria, and reduced sequences for the genera Prevotella and Veillonella, and Phylum
Fusobacteria compared to normal control subjects [23]. Our data are partly in agreement with
the reported reduction in Prevotella. Goleva et al further showed that the bacterium that was
overexpressed in these patients, Haemophilus parainfluenzae, can directly induce
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corticosteroid resistance. In addition, Th-17 cells may be induced by bacterial infections and
this has been implicated in corticosteroid insensitivity [45, 46].
Interestingly, the sputum culture results did not correlate with what was observed from the
16s rRNA analysis with positive cultures of Haemophilus influenzae,Moraxella catarrhalis and
Staphylococcus aureus being most commonly observed in the asthmatic samples. This may not
be surprising given the fact that sputum culture results will depend to a large extent on the
media on which the bacteria are grown. On the other hand, DNA-based assays of microbiota
does not allow one to determine the activity of members of the microbial community. A more
comprehensive approach to culturing these bacteria is needed.
One potential weakness of our study is the inevitable contamination of the upper airway
microflora in the sputum samples. However, this contamination would have been similar for all
subjects although the upper airway microbiota would also be influenced by the oral and dental
state and the presence of comorbidities such as rhinosinusitis, laryngitis or gastrooesophageal
reflux. The microbiota we found in this study is quite distinct from that described in various
compartments of the upper airway and oral cavity such as saliva, nasopharynx and nose [47, 48].
Even in studies that have directly sampled the lower airways through a bronchoscope for brush-
ings, biopsies or bronchoalveolar lavage fluid, there may have been contamination brought on
by the passage of the bronchoscope through the upper airways prior to getting to the lower air-
ways. At the other extreme, there is the suggestion that the bacteria found in the lower airway
represents contamination of bacteria from the upper airways [49]. However, part of this micro-
biota is unique representing an adaptation towards proliferation in the lung environment [50]. It
is important that such a study was performed in sputum samples because this is the most non-
invasive way of obtaining lower airway samples relatively safely from patients, and will represent
the only acceptable method of obtaining lower airway samples from all patients with asthma.
While the 16S rRNA gene sequencing approach to define microbiota provides us with the
bacterial members of the airway microbiota, it does not provide us with the fungi and viruses
potentially present in the lower airways. Their potential contribution therefore is missed by
using this approach. Another limitation of our cross-sectional study is that we are looking at a
single time point and therefore are restricted in terms of the dynamic nature of the microbiota
in severe asthma. Longitudinal studies would be advantageous but far from trivial when balanc-
ing the clinical care of patients with such severe disease and repeated invasive sampling. In
addition, dormancy is common in microbial communities and activity of community members
ideally requires a direct measure of activity such as RNA, protein or metabolic assays or serial
sampling (requiring longitudinal studies) that we were unable to perform here. Finally, there
are other alternative analytical methods available in the microbiome literature that could have
been used in our study, but we have here restricted ourselves to the most commonly used
methods in the absence of bench-marking studies. For example, there are many different and
novel statistical tests available for comparing OTUs and other phylogenetic levels in micro-
biome studies, but no bench-marking. We have therefore resorted to use a well-established sta-
tistical test corrected for multiple testing.
In summary, we have shown that in severe asthma, there is a distinct alteration of the spu-
tum microbiota with a greater prominence of Firmicutes (including 2 Streptococcal OTUs, and
a lower prominence of Bacteroidetes, particularly Prevotella spp. These bacterial OTUs were
related to distinct components of the severe asthma syndrome, particularly those relating to
the use of oral corticosteroids. Analysis of 16S rRNA gene sequences differentiates poorly
between different streptococcal species, and further classification by typing additional poly-
morphic loci [18] as well as cultures of streptococcal isolates is desirable in future studies. In
addition, the potential role of these streptococcal species in the pathogenesis of severe asthma
will need further investigation.
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